воскресенье, 27 ноября 2016 г.

Robert W. Baird Reaffirms Neutral Rating for Biogen Inc.

Robert W. Baird Reaffirms Neutral Rating for Biogen Inc.


's stock had its "neutral" rating reiterated by equities researchers at Robert W. Baird in a report issued on Saturday. They presently have a $284.00 target price on the biotechnology company's stock.



from Biotech News